medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2003, Número 3

<< Anterior Siguiente >>

Ann Hepatol 2003; 2 (3)


Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: Analysis of mexican patients included in a multicenter international clinical trial

Bosques-Padilla F, Trejo-Estrada R, Campollo-Rivas O, Cortez-Hernández C, Dehesa-Violante M, Maldonado-Garza H, Pérez-Gómez R, Cabrera-Valdespino A

Idioma: Ingles.
Referencias bibliográficas: 19
Paginas: 135-139
Archivo PDF: 68.52 Kb.


FRAGMENTO

Sin resumen


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Thomas HC, Torok ME, Forton DM, Taylor-Robinson SD. Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C. J Hepatol 1999; 31 Suppl 1: 152–9.

  2. EASL International Consensus Conference on hepatitis C: Paris, 26–28 February, 1999: consensus statement. J Hepatol 1999; 30: 956–61.

  3. 3 Booth JC, O’Grady J, Neuberger J. Clinical guidelines on the management of hepatitis C. Gut 2001; 49 Suppl 1: I-1.

  4. Canadian Association for the Study of the Liver. Canadian consensus conference on the management of viral hepatitis. Can J Gastroenterol 2000; 14 Suppl B: 5B–20B.

  5. Lai MY, Kao JH, Yang PM, et al. Long-term efficacy of ribavirin plus interferon alpha in the treatment of chronic hepatitis C. Gastroenterology 1996; 111: 1307–12.

  6. Poynard T, Marcellin P, Lee SS, et al. Randomized trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426–32.

  7. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485–92.

  8. Reddy KR, Wright TL, Pockros PJ, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33: 433–8.

  9. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666–72.

  10. Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673–80.

  11. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395–403.

  12. Pockros PJ, Carithers R, Desmond P, et al. Evaluation of two doses of peginterferon alfa-2a for the treatment of chronic hepatitis C (CHC). In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December 16–19, 2001. Washington, D.C.: American Society for Microbiology, 2002: 285 (abstract).

  13. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958–65.

  14. Xu Z-X, Hoffman J, Patel I, Joubert P. Single-dose safety/tolerability and pharmacokinetics/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated-interferon (PEG-IFN) and interferon a-2a (IFN a-2a) to healthy subjects. Hepatology 1998; 28: Suppl: 702A (abstract).

  15. Nieforth KA, Nadeau R, Patel IH, Mould D. Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects. Clin Pharmacol Ther 1996; 59: 636–46.

  16. Wills RJ. Clinical pharmacokinetics of interferons. Clin Pharmacokinet 1990; 19: 390–9.

  17. Algranati NE, Sy S, Modi M. A branched methoxy 40 kDa polyethylene glycol (PEG) moiety optimizes the pharmacokinetics (PK) of peginterferon a-2a (PEG-IFN) and may explain its enhanced efficacy in chronic hepatitis C (CHC). Hepatology 1999; 30 Suppl: 190A (abstract).

  18. Germer JJ, Rys PN, Thorvilson JN, Persing DH. Determination of hepatitis C virus genotype by direct sequence analysis of products generated with the Amplicor HCV test. J Clin Microbiol 1999; 37: 2625–30.

  19. Ferenci P, Shiffman ML, Fried MW, et al. Early prediction of response to 40 kDa peginterferon alfa-2a (Pegasys) plus ribavirin (RBV) in patients with chronic hepatitis C (CHC). Hepatology 2001; 34: 351A (abstract).




2020     |     www.medigraphic.com